PARP inhibitors for hereditary breast cancer with germline BRCA mutation

被引：0
作者：
Im, Seock-Ah [1 ]
机构：
[1] Seoul Natl Univ, Canc Res Inst, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.426
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PSY8-3
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [41] Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
    Emiroglu, Selman
    Ozkurt, Enver
    Cabioglu, Neslihan
    Igci, Abdullah
    Saip, Pinar
    Yazici, Hulya
    Ozmen, Tolga
    Ozmen, Vahit
    Muslumanoglu, Mahmut
    Tukenmez, Mustafa
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 163 - 173
  • [42] A PALB2 germline mutation associated with hereditary breast cancer in Italy
    Laura Papi
    Anna Laura Putignano
    Caterina Congregati
    Irene Piaceri
    Ines Zanna
    Francesco Sera
    Doralba Morrone
    Maurizio Genuardi
    Domenico Palli
    Familial Cancer, 2010, 9 : 181 - 185
  • [43] The Role of PARP Inhibitors in Germline BRCA-Associated Pancreatic Ductal Adenocarcinoma
    Moffat, Gordon T.
    O'Reilly, Eileen M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (03) : 168 - +
  • [44] Impact of BRCA mutation status on the clinical phenotype and survival of hereditary breast cancer
    Kiechle, M.
    Engel, C.
    Schmutzler, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Determination of a BRCA1 gene mutation in a family with hereditary breast cancer
    Gallardo, M
    Faúndez, P
    Cruz, A
    Rodríguez, M
    Alvarez, M
    Carvallo, P
    REVISTA MEDICA DE CHILE, 2004, 132 (02) : 203 - 210
  • [46] Hereditary breast cancer in Latvia: Mutation analysis of the BRCA1 gene
    Tihomirova, L
    Csokay, B
    Stengrevics, A
    Sinicka, O
    Kamerade, R
    Olah, E
    DISEASE MARKERS, 1999, 15 (1-3) : 97 - 97
  • [47] A PALB2 germline mutation associated with hereditary breast cancer in Italy
    Papi, Laura
    Putignano, Anna Laura
    Congregati, Caterina
    Piaceri, Irene
    Zanna, Ines
    Sera, Francesco
    Morrone, Doralba
    Genuardi, Maurizio
    Palli, Domenico
    FAMILIAL CANCER, 2010, 9 (02) : 181 - 185
  • [48] Impact of BRCA mutation status on the clinical phenotype and survival of hereditary breast cancer
    Kiechle, M.
    Engel, C.
    Schwarz-Boeger, U.
    Grund, D.
    Preisler-Adams, S.
    Crohns, C.
    Stark, S.
    Gadzicki, D.
    Strunz, K.
    Schoenbuchner, I
    Nestle-Kraeemeling, C.
    Kast, K.
    Ditsch, N.
    Schlehe, B.
    Schmutzler, R.
    CANCER RESEARCH, 2009, 69 (02) : 229S - 229S
  • [49] PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
    Shao, Fengping
    Duan, Yaoyun
    Zhao, Yunhe
    Li, Yinguang
    Liu, Jun
    Zhang, Cai
    He, Shanyang
    AGING-US, 2021, 13 (06): : 8975 - 8988
  • [50] PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
    Layman, Rachel M.
    Arun, Banu
    CANCER JOURNAL, 2021, 27 (01) : 67 - 75
12345